From MarketBeat:

Pfizer reported earnings of $0.10 per share for the quarter, beating analysts’ estimates by $0.28. The company’s quarterly revenue of $14.25 billion fell short of analyst estimates, with a 41.3% decrease from the previous year. Pfizer’s updated guidance for FY24 is $2.05-2.25 EPS.

Pfizer stock traded at $27.12 on Tuesday, with a 52-week low of $25.76 and a 52-week high of $44.46. The company’s debt-to-equity ratio is 0.63, with a market capitalization of $153.13 billion and a dividend yield of 6.19%.

Several brokerages commented on Pfizer’s stock, with 13 hold ratings and 5 buy ratings. The company currently has an average target price of $38.22 from Wall Street analysts.

Institutional investors own 68.05% of Pfizer’s stock. Hedge funds have recently increased their positions in the company, demonstrating confidence in its future growth.
Pfizer Inc. offers a wide range of biopharmaceutical products across various therapeutic areas, including cardiovascular metabolic, infectious diseases, and COVID-19 prevention and treatment under multiple brands.

This news alert was generated by narrative science technology for speed and accuracy in reporting. Pfizer did not make the top five stocks recommended by top-rated analysts.
AI technology can help investors build wealth through AI stocks. For free access to this report, click the link above.



Read more: Pfizer (NYSE:PFE) Issues Earnings Results, Beats Expectations By $0.28 EPS